The primary reason for this discrepancy is that binding is merely a physical docking event while function requires a specific biological change. When scientists use a peptide service to find binders, they often work with purified proteins in a simplified environment. This setting does not mimic the complex interior of a living cell. There are several specific reasons why a peptide might bind tightly but fail to work as a drug candidate:

(i) The Binding Site Location
A peptide might bind to a region of the protein that is not involved in its activity. These are often called silent binders. If the peptide does not block an active site or induce a structural change, the protein continues to function normally despite being bound.

(ii) Physical Access Issues
In a library screening, the target is often easily accessible. In a cell based assay, the peptide must survive the extracellular environment and potentially cross the cell membrane. Many peptides identified in phage display are too large or too polar to enter the cell.

(iii) Protein Folding Variations
The recombinant protein used for the initial screening might lack the post translational modifications or the specific folding patterns that the protein has when it is produced inside a human cell. This means the peptide may not recognize the target in its truly natural state.

When moving from initial discovery to bench level testing, the requirements for the peptide library change significantly. A custom peptide library meant for cell assays needs to meet higher standards than one used for simple binding tests. Researchers usually focus on the following aspects:

(i) Purity Requirements
For the very first round of screening, crude peptides are often acceptable to save on costs. However, for functional assays, impurities can cause toxic effects or false positives. Purity levels should typically be above 90 percent to ensure the biological effect is caused by the sequence itself.

(ii) The Use of Chemical Modifications
Natural peptides are often chewed up by enzymes within minutes. A professional peptide service can introduce modifications like D-amino acids or cyclization. These changes help the peptide survive longer in the cell culture medium during the experiment.

(iii) Scale and Concentration
Cell based experiments often require larger amounts of material than binding assays. It is important to ensure that the peptide library synthesis provides enough mass to perform dose response curves across multiple cell lines.

Flow cytometry is a powerful tool because it allows researchers to look at individual cells rather than just the average of the whole population. After a peptide library screening identifies a potential lead, flow cytometry provides a deeper layer of data. This service is used to verify several different factors:

(i) Internalization and Localization
By attaching a fluorescent tag to the peptide, scientists can see if the peptide actually enters the cell or if it just sticks to the outside. This is a critical piece of data for any intracellular target.

(ii) Binding to Native Targets
Flow cytometry can confirm that the peptide binds to the target when it is expressed on the surface of a live cell. This is often more reliable than using an isolated protein on a plastic plate.

(iii) Cell Health Monitoring
The technology can simultaneously measure markers of cell stress or death. This helps researchers see if the peptide is causing the desired effect or if it is simply making the cells sick in a non-specific way.

Identifying a lead that kills or inhibits cells is only useful if the effect is specific to the target. Cytotoxicity testing services are designed to rule out peptides that are broadly toxic. These experiments measure different aspects of cell health:

(i) Membrane Integrity Assays
The LDH release assay is a standard method here. When a cell membrane is damaged, the enzyme lactate dehydrogenase leaks into the surrounding liquid. High levels of this enzyme indicate that the peptide is likely punching holes in the cell membrane.

(ii) Metabolic Activity Tests
Assays like MTT or XTT measure how well the mitochondria are working. If the cells stop processing these reagents, it means their metabolism is failing. This is a common way to measure growth inhibition.

(iii) Detection of Programmed Cell Death
Researchers look for specific markers like caspase activation. This helps distinguish between a peptide that causes a clean, programmed death and one that causes messy, necrotic damage to the tissue.